| Project/Area Number |
17K16692
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2018: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 骨肉腫 / エクソソーム / miRNA / MSC由来エクソソーム / 転移 / 骨軟部腫瘍 / 転移メカニズム |
|---|
| Outline of Final Research Achievements |
We selected miRNA143, miRNA26a, miRNA 23a which may be associated with the metastasis and growth of osteosarcoma. After transfection each miRNA into MSC, we collected each MSC derived exosome which was extracted from MSC and administrated these exosomes into mice model of osteosarcoma.However, there was not the significant difference.We will administrate exosomes which mixed two kinds or more and investigate effects to the osteosarcoma mice model in future.On the other hand, we are going to continue examining the relations between osteosarcoma with miRNA26,miRNA23 using miRNA26 or miRNA23 knockout mice.
|
| Academic Significance and Societal Importance of the Research Achievements |
骨肉腫治療は未だに、化学療法の奏功不十分な症例、転移や再発症例の生存率が約20％未満である。そのため化学療法だけでなく、エクソソーム、miRNAを解析することによりさらなる治療、腫瘍マーカーの発見により生存率の向上に役立つと考えられる。
|
